SG11202000124PA - Promoting hair growth and treatment of hair loss or excessive hair shedding - Google Patents

Promoting hair growth and treatment of hair loss or excessive hair shedding

Info

Publication number
SG11202000124PA
SG11202000124PA SG11202000124PA SG11202000124PA SG11202000124PA SG 11202000124P A SG11202000124P A SG 11202000124PA SG 11202000124P A SG11202000124P A SG 11202000124PA SG 11202000124P A SG11202000124P A SG 11202000124PA SG 11202000124P A SG11202000124P A SG 11202000124PA
Authority
SG
Singapore
Prior art keywords
hair
international
subject
shedding
excessive
Prior art date
Application number
SG11202000124PA
Other languages
English (en)
Inventor
Rodney Sinclair
Original Assignee
Samson Clinical Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017902722A external-priority patent/AU2017902722A0/en
Application filed by Samson Clinical Pty Ltd filed Critical Samson Clinical Pty Ltd
Publication of SG11202000124PA publication Critical patent/SG11202000124PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
SG11202000124PA 2017-07-12 2018-07-12 Promoting hair growth and treatment of hair loss or excessive hair shedding SG11202000124PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2017902722A AU2017902722A0 (en) 2017-07-12 Promoting hair growth and treatment of hair loss or excessive hair shedding
PCT/AU2018/050719 WO2019010535A1 (en) 2017-07-12 2018-07-12 STIMULATION OF HAIR GROWTH AND TREATMENT OF HAIR FALL OR EXCESSIVE ALOPECIA

Publications (1)

Publication Number Publication Date
SG11202000124PA true SG11202000124PA (en) 2020-02-27

Family

ID=65001077

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202000124PA SG11202000124PA (en) 2017-07-12 2018-07-12 Promoting hair growth and treatment of hair loss or excessive hair shedding

Country Status (10)

Country Link
US (2) US20190269684A1 (https=)
EP (1) EP3651769B1 (https=)
JP (2) JP7191927B2 (https=)
KR (2) KR20240064747A (https=)
CN (1) CN111065396A (https=)
AU (2) AU2018250398B2 (https=)
CA (1) CA3069336A1 (https=)
ES (1) ES2909395T3 (https=)
SG (1) SG11202000124PA (https=)
WO (1) WO2019010535A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015337807B2 (en) 2014-10-29 2017-05-04 Samson Clinical Pty Ltd Detection and treatment of excessive hair shedding
US12364696B2 (en) 2019-02-27 2025-07-22 Jak Slave Pty Ltd Treatment of autoimmune disease
EP4114362A4 (en) * 2020-03-05 2024-03-20 University of Miami CANNABIDIOL NANOMEDICINE FORMULATIONS AND METHODS OF USE THEREOF
CN112691187B (zh) * 2020-12-30 2021-12-21 深圳新发源植物科技发展有限公司 一种用于防止额前脱发的缓释膜及其制备方法
CN113248501B (zh) * 2021-06-17 2021-10-08 南京韦尔优众医药有限公司 Cly系列化合物及其制备方法和制备药物的用途
AU2023366929A1 (en) * 2022-10-25 2025-05-08 Veradermics, Incorporated Compositions and methods of use for modified release minoxidil
JP2025531956A (ja) * 2023-09-01 2025-09-29 フォリア インターナショナル 脱毛症の処置用の経口ミノキシジルに対する経口サプリメントの組成物及び方法
WO2025051237A1 (zh) * 2023-09-08 2025-03-13 苏州开拓药业股份有限公司 含雄激素受体抑制剂/拮抗剂的药物组合物及方法和用途
GB2638418A (en) * 2024-02-21 2025-08-27 Novumgen Ltd An orodispersible tablet of spironolactone and its process of preparation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4997643A (en) * 1989-07-12 1991-03-05 Union Carbide Chemicals And Plastics Company Inc. Polymeric salt delivery systems
GB2314019B (en) * 1996-06-10 2000-03-15 Bio Scient Ltd The use of L-Lysine in the treatment of hair loss
AU2406299A (en) * 1998-02-12 1999-08-30 Centrapharm Inc. Sublingual drug formulations having combined rapid onset of action and long lasting therapeutic effect
US20050271596A1 (en) * 2002-10-25 2005-12-08 Foamix Ltd. Vasoactive kit and composition and uses thereof
WO2006038315A1 (ja) * 2004-10-07 2006-04-13 Kabushiki Kaisha Sangi 経皮・経粘膜吸収製剤
JP2009091325A (ja) * 2007-10-11 2009-04-30 Rohto Pharmaceut Co Ltd 育毛剤
CA2737025C (en) * 2008-09-27 2012-09-04 Jina Pharmaceuticals, Inc. Lipid based pharmaceutical preparations for oral and topical application; their compositions, methods, and uses thereof
EP2510930A1 (en) * 2011-04-15 2012-10-17 Bionanoplus, S.L. Nanoparticles comprising half esters of poly (methyl vinyl ether-co-maleic anhydride) and uses thereof
AU2011100917B4 (en) * 2011-07-26 2013-05-02 Sinclair, Rodney Daniel Professor Treatment of male and female androgenetic alopecia with oral minoxidil either alone or in combination with antiandrogens
WO2013181487A2 (en) * 2012-05-31 2013-12-05 Stiefel Laboratories, Inc. Method of treating
AU2015337807B2 (en) * 2014-10-29 2017-05-04 Samson Clinical Pty Ltd Detection and treatment of excessive hair shedding
US9561224B1 (en) * 2015-05-27 2017-02-07 Moshe Rogosnitzky Methods and compositions for treating androgenetic alopecia

Also Published As

Publication number Publication date
EP3651769A4 (en) 2021-04-21
JP2023016964A (ja) 2023-02-02
AU2019203438A1 (en) 2019-06-06
EP3651769A1 (en) 2020-05-20
EP3651769B1 (en) 2022-01-05
BR112020000508A2 (pt) 2020-07-14
KR102663164B1 (ko) 2024-05-07
US20250064807A1 (en) 2025-02-27
AU2018250398A1 (en) 2019-01-31
KR20240064747A (ko) 2024-05-13
NZ760579A (en) 2024-09-27
US20190269684A1 (en) 2019-09-05
CA3069336A1 (en) 2019-01-17
JP2020527146A (ja) 2020-09-03
KR20200028403A (ko) 2020-03-16
ES2909395T3 (es) 2022-05-06
JP7191927B2 (ja) 2022-12-19
AU2018250398B2 (en) 2019-02-28
CN111065396A (zh) 2020-04-24
WO2019010535A1 (en) 2019-01-17

Similar Documents

Publication Publication Date Title
SG11202000124PA (en) Promoting hair growth and treatment of hair loss or excessive hair shedding
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201909960UA (en) Methods for improving memory and cognition and for treating memory and cognitive disorders
SG11201906431UA (en) Method for the treatment of thromboembolism
SG11201907023UA (en) Method of reducing neutropenia
SG11201810420YA (en) Antibodies to alpha-synuclein and uses thereof
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201909963YA (en) Methods for treating dravet syndrome
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201804704PA (en) Compositions and methods for decreasing tau expression
SG11201901996UA (en) Formulations of ( r)-2-amino-3-phenylpropyl carbamate
SG11201908420WA (en) Compositions of plinabulin and use thereof
SG11201901534VA (en) Combination therapy with controlled-release cnp agonists
SG11201805001UA (en) Method of treating influenza a
SG11201904535VA (en) Prevention and treatment of bone and cartilage damage or disease
SG11201810872UA (en) Composition and method for reducing neutropenia
SG11201900021PA (en) Methods and compositions for the treatment of cancer
SG11201909882SA (en) Targeted neoepitope vectors and methods therefor
SG11201906778RA (en) Improved methods for assessing risk of developing breast cancer
SG11201805149XA (en) Compositions comprising 15-hepe and methods of using the same
SG11201803643TA (en) Virulence attenuated bacteria for treatment of malignant solid tumors
SG11201809882XA (en) Pharmaceutical combinations for treating cancer
SG11201909107YA (en) Stenosis treatment
SG11201811763SA (en) B-cell-mimetic cells
SG11201805755SA (en) Methods of administering hepcidin